Details

Autor(en) / Beteiligte

• Isfan, F
• Kanold, J
• Merlin, E
• Contet, A
• Sirvent, N
• Rochette, E
• Poiree, M
• Terral, D
• Carla-Malpuech, H
• Reynaud, R
• Pereira, B
• Chastagner, P
• Simeoni, M C
• Auquier, P
• Michel, G
• Deméocq, F

Titel

Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA)

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2012-05, Vol.47 (5), p.684-693

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormone (GH) therapy on growth rate and final height (FH) in these children. We evaluated growth rates during the pre- and post-transplant periods to FH in a group of 25 children treated with HSCT ( n =22), TBI ( n =21) or/and CI ( n =8) for AL and receiving GH therapy. At the start of GH treatment, the median height Z -score was −2.19 (−3.95 to 0.02), significantly lower than at AL diagnosis ( P <0.001). Overall height gain from start of GH treatment to FH was 0.59 Z (−2.72 to 2.93) with a median height Z -score at FH of −1.35 (−5.35 to 0.27). This overall height gain effect was greater in girls than in boys ( P =0.04). The number of children with heights in the reference population range was greater after than before GH therapy ( P =0.07). At FH the GVHD and GH treatments lasting <2 years were associated with shorter FH ( P =0.02 and 0.05). We found a measurable beneficial effect of GH treatment on growth up to FH.